CanSino Plans Phase 3 COVID-19 Vaccine Trial in Saudi Arabia

CanSino Biologics is preparing a phase 3 trial of its COVID-19 vaccine in Saudi Arabia, the country’s Ministry of Health announced.

The study will include at least 5,000 healthy participants over age 18, who will be given either a low dose of the vaccine or the vaccine without any active ingredients.

CanSino’s vaccine has shown efficacy in early phase trials, generating antibodies and good immune responses in the volunteers.